Anti-tumour necrosis factor-α therapy for severe enteropathy in patients with common variable immunodeficiency (CVID)

Clinical and Experimental Immunology

Volumn 150, Issue 2, 2007, Pages 306-311

  Chua, I ^a   Standish, R ^a   Lear, S ^a   Harbord, M ^b   Eren, E ^b   Raeiszadeh, M ^a   Workman, S ^a   Webster, D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Anti TNF therapy; CMV; Common variable immunodeficiency; Inflammatory bowel disease; Infliximab

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; BUDENOFALK; BUDESONIDE; COLESTYRAMINE; GANCICLOVIR; INFLIXIMAB; PANCREATIN; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; BONE DENSITOMETRY; CASE REPORT; CLINICAL TRIAL; COLITIS; COLON BIOPSY; COMMON VARIABLE IMMUNODEFICIENCY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENUM BIOPSY; ENTERITIS; ENTEROPATHY; FEMALE; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; LACTOBACILLUS; LOOSE FECES; MALE; MOUTH ULCER; OSTEOPOROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; STEATORRHEA; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; ANTIBODIES, MONOCLONAL; COLON; COMMON VARIABLE IMMUNODEFICIENCY; DUODENUM; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35348965735     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03481.x     Document Type: Article

References (16)

1. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency. Clinical and immunological features of 248 patients. Clin Immunol 1999 92 : 34 48.
2. Salzer U, Grimbacher B. Monogenetic defects in common variable immunodeficiency: what can we learn about terminal B cell differentiation? Curr Opin Rheumatol 2006 18 : 377 82.
3. Webster ADB. Common variable immunodeficiency. Immunol Allergy Clinics North America 2001 21 : 1 22.
4. Washington K, Stenzel TT, Buckley RH. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Path 1996 20 : 1240 52.
5. Hermaszewski RA, Webster AD. Primary hypogammaglobuliniemia: a survey of clinical manifestations and complications. Q J Med 1993 86 : 31 42.
6. Teahon K, Webster AD, Price AB, Weston J, Bjarnason I. Studies on the enteropathy associated with primary hypogammaglobulinemia. Gut 1994 35 : 1244 9.
7. Conlong P, Rees R, Shaffer J et al. Primary antibody deficiency and Crohn's disease. Postgrad Med J 1999 75 : 161 4.
8. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance imfliximab for Crohn's disease: the ACCENT I trial. Lancet 2002 359 : 1541 9.
9. Raesizadeh M, Kopycinski J, Paston SJ et al. The T cell response to persistent herpes virus infections in common variable immunodeficiency. Clin Exp Immunol 2006 146 : 234 42.
10. Hommes DW, Sterringa G, Sander JH, van Deverter SJH, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease. Inflamm Bowel Dis 2004 10 : 245 50.
11. Docke WD, Prosch S, Fietze E et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994 343 : 268 9.
12. Mannon P, Fuss I, Dill S et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with non variable immunodeficiency. Gastroenterology 2006 131 : 748 56.
13. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988 10 : 401 5.
14. Hanauer SB. Medical therapy for Crohn's disease. Curr Opin Gastroenterol 1999 15 : 308.
15. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004 50 : 372 9.
16. Carbronero R, Sewell WA, North ME, Webster AD, Farrant J. Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency. J Immunol 2000 164 : 488 94.